Pacylex Pharmaceuticals's Zelenirstat Shows Potent in vitro Radiosensitization in Human Glioblastoma Models

03 Oct 2023
www.biospace.com
Fast TrackOrphan DrugPhase 1
Edmonton, Alberta--(News - October 3, 2023) - Pacylex Pharmaceuticals, a clinical stage pharmaceutical company focused on the development of therapies for hematologic and solid cancers, announced recent results generated at NIH using its lead drug, zelenirstat, presented at the Canadian Association of Radiation Oncology Annual Meeting in Montreal, Canada, on September 23, 2023. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Zelenirstat, a myristoylation inhibitor in clinical development, markedly improved the ability of radiation to kill cultured human brain cancer cells. Zelenirstat was more effective than clinically used radiosensitizers, including temozolomide, cisplatin, and 5-fluorouracil. Orally administered zelenirstat is predicted to cross the blood brain barrier more efficiently than temozolomide, the current standard of care radiosensitizer for aggressive brain cancers. Click image above to view full announcement. About Zelenirstat Zelenirstat (formerly identified as PCLX-001) is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia, lymphoma, and solid tumors. Zelenirstat selectively kills cancer cells in vitro and has been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors in animal models. Zelenirstat is particularly effective against Diffuse Large B Cell Lymphoma (DLBCL) and Acute Myeloid Leukemia (AML)AML) in animal disease models. In AMLAML, it also selectively kills leukemic stem cells in vivo while sparing normal bone marrow cells.Zelenirstat is currently being evaluated in a Phase 1/2a open-label study (NCT04836195) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of zelenirstat in patients with relapsed/refractory (R/R) Non Hodgkin Lymphoma (NHL) and advanced solid malignancies who have progressed on all available standard therapies. About Pacylex Pharmaceuticals Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with orally bioavailable NMT inhibitorsNMT inhibitors. Pacylex has a US Subsidiary in the San Francisco Bay area. Zelenirstat is the lead drug in a new class of NMT inhibitorsNMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1 multiple ascending dose study in Canada in patients with R/R NHL and advanced solid tumors, and a Phase 2a dose expansion in patients with R/R NHL. The IND for a Phase 1 multiple ascending dose study in AMLAML has been cleared and the FDA has granted zelenirstat both Orphan Drug Designation and Fast Track Designation for AMLAML. The US Department of Defense is supporting the initial clinical investigation of zelenirstat in patients with AMLAML. The Cure Cancer Foundation supported initial clinical studies through its World's Longest Games. For additional information, please visit . Twitter @Pacylex ( ) LinkedIn ( ) Facebook ( ) Contacts: Michael Weickert Ph.D 650-218-1840 michael.weickert@pacylex.com Source: Pacylex To view the source version of this press release, please visit
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.